News Epizyme's sarcoma drug tazemetostat faces key vote from FDA ... Epizyme’s sarcoma drug tazemetostat is set to go before an influential FDA advisory committee today, following a mixed review from the agency’s own staffers.
Oncology On nuclear medicine and oncology, SHINE technologies Greg Piefer, founder and CEO of SHINE Technologies, discusses nuclear medicine and the role of radiopharmaceuticals in oncology.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face